Category: DAIC Articles

Innovations Driving the Cath Lab Technology of Tomorrow

May 31, 2019

When Andreas Grüntzig, father of percutaneous transluminal coronary angioplasty, approached his cardiac surgeon colleague Åke Senning for support in applying newly-developed angioplastic techniques to the coronary arteries, Dr. Senning enthusiastically responded, “You will take away my patients, but get started!” Senning foresaw what Grüntzig was setting in motion — the development of the discipline of interventional cardiology, destined to become a field of practice positioned to bring lifesaving therapies to patients whose bodies struggle to recover from the traumatic insult of open surgery.

Visit Website

Explaining Cardiac Conditions to the Layman Using the Old House Analogy

May 28, 2019

Physicians use many strategies to better interface with patients and their families to try and explain in non-physician terms basic cardiac conditions and how the various subspecialties are involved. My favorite is the analogy of cardiac conditions related to owning an old house and all the issues the homeowner can face, including plumbing issues, electrical issues and structural issues. As an owner of a house built in the 1890s and finding myself doing the majority of the constant repairs, I found these comparisons to be spot on.

Visit Website

Medtronic Presents Positive Renal Denervation Results at EuroPCR 2019

May 25, 2019

Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical trial at the 2019 EuroPCR Annual Meeting, May 20-23 in Paris, France. The data indicate that renal denervation (RDN) with the Medtronic Symplicity renal denervation system was associated with reduced occurrence of subclinical atrial fibrillation (AF) in a small subset of high-risk patients with hypertensive heart disease over a median follow-up period of more than two years.

Visit Website

FDA Clears First Anticoagulant for Pediatric Patients With VTE or PE

May 20, 2019

The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older. VTE can include deep vein thrombosis (DVT) and pulmonary embolism (PE), which can lead to death.

Visit Website
Page 3 of 5012345...101520253035404550...»